{
  "target": "Cell Therapy",
  "slug": "cell-therapy",
  "last_reviewed": "2026-02-13",
  "catalysts": [
    {
      "date": "2026-06",
      "date_display": "H1 2026",
      "company": "Eli Lilly / Orna",
      "asset": "ORN-252",
      "description": "IND filing and Phase 1 initiation expected â€” in vivo CD19 CAR-T for autoimmune diseases"
    },
    {
      "date": "2026-06",
      "date_display": "2026",
      "company": "AstraZeneca / EsoBiotec",
      "asset": "EBO-101 (BCMA)",
      "description": "Additional clinical data expected from in vivo lentiviral CAR-T programs"
    },
    {
      "date": "2026-06",
      "date_display": "2026",
      "company": "AbbVie / Capstan",
      "asset": "CPTX-61 (CD19)",
      "description": "Continued clinical development and additional data expected"
    },
    {
      "date": "2026-06",
      "date_display": "2026",
      "company": "Umoja Biopharma",
      "asset": "UB-VV111",
      "description": "Phase 1 data for lentiviral in vivo CAR-T in r/r NHL (Fast Track)"
    },
    {
      "date": "2026-06",
      "date_display": "2026",
      "company": "Kelonia / J&J",
      "asset": "KLN-1010 (BCMA)",
      "description": "Additional clinical data from in vivo retroviral CAR-T program"
    },
    {
      "date": "2026-12",
      "date_display": "H2 2026",
      "company": "BMS / Orbital",
      "asset": "Circular RNA programs",
      "description": "Preclinical/IND-enabling data for in vivo cell therapy programs"
    },
    {
      "date": "2027-06",
      "date_display": "2027",
      "company": "Multiple",
      "asset": "In vivo CAR-T",
      "description": "Phase 1 clinical data from Lilly/Orna (ORN-252), AbbVie/Capstan, AZ/EsoBiotec, and Gilead/Kite programs"
    }
  ]
}
